Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct 9;316(9):667.
doi: 10.1007/s00403-024-03419-w.

Risankizumab in obese patients with moderate-to-severe plaque psoriasis: a 104-week, real-world, retrospective study

Natalia Rompoti #  1 , Ioannis-Alexios Koumprentziotis #  2 , Irene Stefanaki  1 , Charitomeni Vavouli  1 , Marina Papoutsaki  1 , Maria Politou  1 , Pantelis Panagakis  3 , Angeliki Befon  3 , Fiori Kousta  3 , Eleni Lazou  3 , Vasiliki Chasapi  3 , Alexander Stratigos  1 , Electra Nicolaidou  1
Affiliations

Risankizumab in obese patients with moderate-to-severe plaque psoriasis: a 104-week, real-world, retrospective study

Natalia Rompoti et al. Arch Dermatol Res. .
No abstract available

Keywords: Interleukin-23; Obesity; Psoriasis; Risankizumab.

PubMed Disclaimer

References

    1. Armstrong AW, Harskamp CT, Armstrong EJ (2012) The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies. Nutr Diabetes 2(12):e54. Published 2012 Dec 3. https://doi.org/10.1038/nutd.2012.26 - DOI - PubMed - PMC
    1. Pirro F, Caldarola G, Chiricozzi A et al (2021) Impact of body mass index on the efficacy of biological therapies in patients with psoriasis: a real-world study. Clin Drug Investig 41(10):917–925. https://doi.org/10.1007/s40261-021-01080-z - DOI - PubMed - PMC
    1. Ricceri F, Chiricozzi A, Peris K, Prignano F (2022) Successful use of anti-IL-23 molecules in overweight-to-obese psoriatic patients: a multicentric retrospective study. Dermatol Ther 35(11):e15793. https://doi.org/10.1111/dth.15793 - DOI - PubMed
    1. Dragotto M, Capalbo E, Cartocci A et al (2023) Real-life effectiveness of Risankizumab according to body mass index: results of an Italian multicentre retrospective study. J Eur Acad Dermatol Venereol. Published Online April 16. https://doi.org/10.1111/jdv.19117
    1. Rompoti N, Stefanaki I, Panagakis P et al (2024) Real-world effectiveness, drug survival and safety of risankizumab over a period of 2 years in 158 patients with moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol. Published Online March 20. https://doi.org/10.1111/jdv.19956

LinkOut - more resources